The global retinoblastoma therapeutics market has been forecast to increase over the next eight years, from a market value of US$1.7 million to be worth US$2.1 million by 2019.
The rising number of children under four years is creating more cases of retinoblastoma, producing a gap in the market for further drug developments despite the effectiveness of current treatments.
Retinoblastoma (Rb) is a rapidly developing cancer that develops in the cells of retina, the light-detecting tissue of the eye. In the developed world, Rb has one of the best cure rates of all childhood cancers (95-98%), with more than nine out of every ten sufferers surviving into adulthood.
The retinoblastoma therapeutics market is currently dominated by a mixture of off-label and generic drugs such as vincristine, etoposide and carboplatin (VEC regimen). These drugs offer a high cure rate with high safety and efficacy for patients. As the drugs used to treat the disease already have a good level of success, the market has remained largely closed to new entrants.
As a result, there are only two molecules currently in the developmental phase, out of which only one is company-sponsored.
The presence of only two first-in-class drugs suggests that the retinoblastoma drugs pipeline is weak and that pharmaceutical companies may therefore want to expand their product offerings into this field.
For more information on the global retinoblastoma therapeutics market, see the latest research: Global Retinoblastoma Therapeutics Market Report
Follow us on Twitter @CandMResearch
Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.